ATLANTA, Dec. 3, 2010 /PRNewswire/ — Elekta recently received
510(k) clearance from the U.S. Food and Drug Administration for its
XiO® treatment planning software to plan spot scanning. Spot
scanning is a proton therapy delivery method that involves
constructing a highly conformal dose to the tumor by using
thousands of small individual beamlets instead of a single large
beam. This approach enables Intensity Modulated Proton Therapy
(IMPT).

XiO, Elekta’s 3D / Intensity Modulated Radiation Therapy (IMRT)
treatment planning platform, offers proton therapy centers another
option to plan proton deliveries. XiO provides unique tools to
facilitate rapid positioning of spots to construct the dose to the
tumor, in addition to a proven dose calculation algorithm to
optimize each beam.

“The completely automated optimization of the spot deliveries
allows clinicians to produce treatment plans with a high degree of
conformality around the target, therefore, minimizing the dose to
adjacent healthy tissue,” says Virgil Willcut, Vice President of
Product Management, Physics & Research for Elekta Treatment
Planning. “Spot scanning especially is important for pediatric
patients since it provides better normal tissue sparing and lower
neutron doses than conventional proton planning, both of which
reduce the chance of radiation induced side effects for a cohort of
patients that are still developing and have long life
expectancies.”

In clinical use for nearly a decade, XiO is in use at more
proton facilities than any other commercial vendor with a similar
product. To learn more about Elekta’s XiO treatment planning
software, visit www.elekta.com/PT-treatmentplanning.

About Elekta

Elekta is a human care company pioneering significant
innovations and clinical solutions for treating cancer and brain
disorders. The company develops sophisticated, stat

‘/>”/>

SOURCE